Comparison of the efficacy and safety of the most commonly used treatments for oral leukoplakia

Authors

Keywords:

EFFECTIVENESS, MOUTH NEOPLASMS, PHOTOCHEMOTHERAPY, THERAPEUTICS.

Abstract

Introduction: oral leukoplakia is a common premalignant condition in the oral cavity that can progress to oral cancer.  In this study we conducted a systematic review and meta-analysis of multiple investigations.

Objective: to compare the effectiveness and safety of the most common treatments for oral leukoplakia, a premalignant condition in the oral cavity that can develop into cancer.

Methods: different types of retrospective, prospective, systematic review, randomized controlled clinical trials and case reports were included. A total of 16 studies met the inclusion criteria. The treatments evaluated were CO2 laser, recombinant adenovirus p53 (rAD-p53) therapy, photodynamic therapy with 5-aminolevulinic acid and toluidine blue, carbon dioxide laser, indium gallium arsenide diode laser, and nivolumab. Results showed variability in response to treatment, with  success rates ranging from 36 % to 100 %.

Results: the results of this systematic review and meta-analysis indicate that commonly used treatments for oral leukoplakia show variability in their effectiveness. Photodynamic therapy and CO2 laser appear to be effective options, although further research is needed to confirm these findings.

Conclusions: It is important to consider that the response to treatment may vary in each patient and lesion, so individualized evaluation is recommended to determine the best therapeutic option.

 

Downloads

Download data is not yet available.

References

1. Campos WG de, Esteves CV, Gallo C de B, Domaneschi C, Aranha ACC, Lemos CA. Treatment of oral leukoplakia with CO2 laser (10,600 nm): analysis of 37 cases. Braz Oral Res [Internet]. 2022 [citado el 12 de marzo de 2024]; 36:e014. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35081231/

2. Hosmani J, Mushtaq S, Abullais SS, Almubarak HM, Assiri K, Testarelli L, et al. Recombinant human Adenovirus-p53 therapy for the treatment of oral leukoplakia and oral squamous cell carcinoma: A systematic review. Medicina (Kaunas) [Internet]. 2021 [citado el 12 de marzo de 2024]; 57(5): 438. Disponible en: https://www.mdpi.com/1648-9144/57/5/438

3. Di Stasio D, Romano A, Russo D, Fiori F, Laino L, Caponio VCA, et al. Photodynamic therapy using topical toluidine blue for the treatment of oral leukoplakia: A prospective case series. Photodiagnosis Photodyn Ther [Internet]. 2020 [citado el 14 de marzo de 2024]; 31:101888. Disponible en: http://dx.doi.org/10.1016/j.pdpdt.2020.101888

4. Yan Y, Li Z, Tian X, Zeng X, Chen Q, Wang J. Laser-assisted photodynamic therapy in proliferative verrucous oral leukoplakia. Photodiagnosis Photodyn Ther [Internet]. 2022 [citado el 14 de marzo de 2024]; 39: 103002. Disponible en: http://dx.doi.org/10.1016/j.pdpdt.2022.103002

5. Birkeland AC, Kademani D, Moore MG, Blair EA. Practice patterns for initial management of oral leukoplakia amongst otolaryngologists and oral and maxillofacial surgeons. Oral Oncol [Internet]. 2023 [citado el 14 de marzo de 2024]; 139: 106341. Disponible en: http://dx.doi.org/10.1016/j.oraloncology.2023.106341

6. Pentenero M, Sutera S, Lodi G, Bagan JV, Farah CS. Oral leukoplakia diagnosis and treatment in Europe and Australia: Oral Medicine Practitioners’ attitudes and practice. Oral Dis [Internet]. 2022 [citado el 14 de marzo de 2024]; 29(8): 3214–22. Disponible en: http://dx.doi.org/10.1111/odi.14301

7. Ou J, Gao Y, Li H, Ling T, Xie X. Application of 5-aminolevulinic acid-mediated Waterlase-assisted photodynamic therapy in the treatment of oral leukoplakia. Sci Rep [Internet]. 2022 [citado el 15 de marzo de 2024]; 12(1): 1–9. Disponible en: https://www.nature.com/articles/s41598-022-13497-3

8. Yang S-W, Lee Y-S, Chang L-C, Hwang C-C, Chen T-A. Clincopathological characteristics and treatment outcomes of oral leukoplakia by carbon dioxide laser excision in the elderly patients. Head Neck [Internet]. 2020 [citado el 15 de marzo de 2024]; 42(5): 1014–23. Disponible en: http://dx.doi.org/10.1002/hed.26074

9. Yilin Y, Shi L, Wang Y, Shen X, Ye S, Tang G, et al. Ablative fractional laser-assisted photodynamic therapy vs. ablative fractional laser for oral leukoplakia treatment: A randomized, controlled pilot study. Photodiagnosis Photodyn Ther [Internet]. 2021 [citado el 15 de marzo de 2024]; 36: 102523. Disponible en: http://dx.doi.org/10.1016/j.pdpdt.2021.102523

10. Yujie Y, Li Z, Tian X, Zeng X, Chen Q, Wang J. Laser-assisted photodynamic therapy in proliferative verrucous oral leukoplakia. Photodiagnosis Photodyn Ther [Internet]. 2022 [citado el 15 de marzo de 2024]; 39: 103002. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35809828/

11. Romeo U, Mohsen M, Palaia G, Bellisario A, Del Vecchio A, Tenore G. CO2 laser ablation of oral leukoplakia: with or without extension of margins? Clin Ter [Internet]. 2020 [citado el 15 de marzo de 2024]; 171(3): e209-e215. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32323707/

12. Almeida J, Silva LV de O, Kato C de NA de O, Pinheiro J de JV, Abreu LG, Silva TA, et al. Management of oral leukoplakia with an 808-nm high-power diode laser: a single-center experience. Lasers Med Sci [Internet]. 2023 [citado el 15 de marzo de 2024]; 38(141). Disponible en: http://dx.doi.org/10.1007/s10103-023-03806-1

13. Zhang Q, Wang F, Liang J, Kuang W, Zeng X, Zhang X. Photodynamic therapy for extensive oral verrucous/granular leukoplakia with moderate-to-severe dysplasia: A case study. Photodiagnosis Photodyn Ther [Internet]. 2022 [citado el 15 de marzo de 2024]; 39: 102910. Disponible en: http://dx.doi.org/10.1016/j.pdpdt.2022.102910

14. Zhang R, Gao T, Wang D. Photodynamic therapy (PDT) for oral leukoplakia: a systematic review and meta-analysis of single-arm studies examining efficacy and subgroup analyses. BMC Oral Health [Internet]. 2023 [citado el 15 de marzo de 2024]; 23(1): 568. Disponible en: http://dx.doi.org/10.1186/s12903-023-03294-3

15. Wan W, Gao X, Song S, Peng J, Jiang C, Fang C, et al. 5-aminolevulinic acid photodynamic therapy for extensive oral leukoplakia with concomitant oral submucous fibrosis: A case report. Photodiagnosis Photodyn Ther [Internet]. 2023 [citado el 15 de marzo de 2024]; 41: 103203. Disponible en: http://dx.doi.org/10.1016/j.pdpdt.2022.103203


16. Hanna GJ, Villa A, Nandi SP, Shi R, ONeill A, Liu M, et al. Nivolumab for patients with high-risk oral leukoplakia: A nonrandomized controlled trial. JAMA Oncol [Internet]. 2024 [citado el 15 de marzo de 2024]; 10(1): 32-41. Disponible en: https://jamanetwork.com/journals/jamaoncology/fullarticle/2811991

Downloads

Published

2025-03-08

How to Cite

1.
González-Cardona Y, Paucar-Cepeda EM, Salina-Arcos M de los A. Comparison of the efficacy and safety of the most commonly used treatments for oral leukoplakia. Univ. Méd. Pinareña [Internet]. 2025 Mar. 8 [cited 2025 Apr. 16];21(1):a1413. Available from: https://revgaleno.sld.cu/index.php/ump/article/view/1413

Issue

Vol. 21 No. 1 (2025): Publicación Continua

Section

Original Article

License

Authors who have published with this journal accept the following terms: authors will retain their copyright and guarantee the journal the right of first publication of their work, which will be simultaneously subject to the Creative Commons recognition license that allows third parties to share the work as long as its author is indicated and its first publication is this journal. Authors may adopt other non-exclusive license agreements for the distribution of the version of the published article (e.g., deposit it in an institutional telematic archive or publish it in a monographic volume) provided that the initial publication in this journal is indicated. Authors are permitted and encouraged to disseminate their article using Internet (e.g., in institutional telematic archives or on their website) before and during the submission process, which may lead to interesting exchanges and increased citations of the published work. (See The Effect of Open Access).